The study team, led by Reza Zabihi of the Student Research Committee at Babol University of Medical Sciences together with colleagues from the university’s departments of internal medicine, social determinants of health, and infectious diseases research, designed the investigation as a matched-style comparison rather than a simple survey of liver patients. They enrolled 37 hospitalized COVID-19 patients with documented pre-existing chronic liver disease and selected 77 comparison patients who were hospitalized with confirmed COVID-19 but had neither chronic liver disease nor other documented chronic comorbidities. This deliberate selection of a relatively clean comparison group is analytically important: by stripping away diabetes, cardiovascular disease, and other common confounders, the researchers sought to isolate the contribution of liver pathology itself to COVID-19 outcomes, rather than the contribution of multimorbidity in general.

The demographic profiles of the two groups were closely aligned. The mean age in the chronic liver disease group was 57.03 years with a standard deviation of 13.85, while the comparison group averaged 55.05 years with a standard deviation of 14.42, a difference that did not reach statistical significance. This age matching matters because age is among the strongest predictors of severe COVID-19, and any meaningful gap in age distribution could have distorted the apparent effect of liver disease. Within the liver disease group, cirrhosis dominated the diagnostic landscape, accounting for 45.9 percent of cases, making advanced scarring of the liver the single most common underlying hepatic disorder among the affected patients.

The laboratory data revealed a striking biochemical signature distinguishing the liver disease cohort. Patients with chronic liver disease showed significantly higher serum levels of aspartate aminotransferase and alanine aminotransferase, the two canonical enzymes released when hepatocytes are injured, as well as elevated bilirubin, the pigment that accumulates when the liver’s processing capacity falters. Their prothrombin times were prolonged, indicating impaired synthesis of clotting factors by a struggling liver, and their blood urea nitrogen levels were elevated, a marker that can reflect dehydration, catabolic stress, or impaired renal perfusion, all common in decompensating cirrhotic patients. These differences were statistically significant at the conventional threshold of P less than 0.05, and together they paint a picture of patients whose hepatic reserve was already compromised before the viral infection added its own burden.

Clinical presentation also diverged between the groups in ways that carry practical implications for frontline physicians. Abdominal pain and confusion were reported more frequently among patients with chronic liver disease. Both symptoms are readily explicable by hepatic pathophysiology: abdominal pain can arise from portal hypertension, ascites stretching the peritoneum, or the capsular distension of an inflamed liver, while confusion in cirrhotic patients frequently signals hepatic encephalopathy, the neuropsychiatric syndrome caused when the failing liver fails to clear ammonia and other neurotoxic metabolites from the circulation. The overlap between encephalopathy and the confusion of severe COVID-19 hypoxia presents a genuine diagnostic challenge, and the study’s finding underscores that clinicians evaluating a confused COVID-19 patient with known liver disease must consider both mechanisms simultaneously.

The central result of the study concerns survival. After accounting for the comparison design, the researchers found that chronic liver disease was associated with higher odds of in-hospital mortality compared with the selected non-CLD comparison group. In other words, even against counterparts who were similar in age and free of other recorded chronic conditions, patients whose livers were chronically diseased died in the hospital at a meaningfully higher rate. This aligns with the mechanistic expectations that motivated the study in the first place. Patients with chronic liver disease are considered particularly vulnerable to COVID-19 because of immune dysregulation, chronic inflammation, and impaired metabolic function, a triad that leaves them less equipped to mount an effective antiviral response and more prone to the runaway inflammatory cascades that characterize severe disease.

The mechanistic plausibility of this vulnerability rests on well-characterized biology. The angiotensin-converting enzyme 2 receptor, which SARS-CoV-2 uses to enter cells, is expressed on cholangiocytes, the epithelial cells lining the bile ducts, providing a potential route for direct viral injury to the biliary tree and, indirectly, to hepatocytes. Beyond direct infection, the systemic inflammation of severe COVID-19, driven by elevated interleukin-6 and C-reactive protein, can precipitate decompensation in a cirrhotic liver that was already operating near its functional ceiling. The coagulopathy of COVID-19, marked by prolonged prothrombin times and elevated D-dimers in the sickest patients, compounds the baseline coagulation abnormalities of advanced liver disease, creating a convergent prothrombotic and prohemorrhagic hazard that neither condition alone would produce to the same degree.

Not every measured outcome differed between the groups, and the negative findings are themselves informative. The duration of hospitalization was statistically indistinguishable between patients with and without chronic liver disease, with a P value of 0.972, suggesting that among those who survived, the liver disease did not prolong the hospital stay in this cohort. The study also evaluated intensive care unit admission as an outcome, alongside demographic characteristics, clinical manifestations, laboratory parameters, and treatment outcomes, providing a broad clinical picture of how the two cohorts fared across the arc of their admissions. Analyses were performed using SPSS version 26, the standard statistical package for medical cohort studies of this scale.

The authors are careful to flag the boundaries of what their data can support. Because subgroup analyses according to cirrhosis status were not performed, no conclusions can be drawn from this cohort regarding the specific association between cirrhosis itself and clinical outcomes, even though cirrhosis was the most common underlying disorder among the liver disease patients. This is a meaningful limitation, since cirrhosis represents the extreme end of the chronic liver disease spectrum, and its specific contribution to COVID-19 mortality has been debated in the international literature. The single-center design at one hospital in Babol, and the modest sample size of 37 exposed patients, further counsel caution in generalizing the effect estimates to other populations and health care settings.

Nevertheless, the study’s practical message for clinicians is clear and actionable. A hospitalized COVID-19 patient with chronic liver disease should be recognized from the outset as belonging to a higher-risk category, warranting closer laboratory surveillance of transaminases, bilirubin, and coagulation parameters, a lower threshold for investigating altered mental status as possible encephalopathy, and heightened vigilance for the decompensation events, such as variceal bleeding, infection, and renal failure, that convert chronic hepatic disease into acute organ failure. The research was approved by the Ethics Committee of Babol University of Medical Sciences under code IR.MUBABOL.REC.1402.155, received no external funding, and was published open access on 6 October 2026, with the authors declaring no competing interests. As the pandemic’s legacy continues to be mapped across vulnerable populations, studies of this kind sharpen the clinical stratification tools that determine which patients need the most aggressive monitoring when SARS-CoV-2 arrives on the ward.

Subject of Research: The association between chronic liver disease and clinical outcomes, including in-hospital mortality, in patients hospitalized with COVID-19.

Article Title: Association of chronic liver disease with clinical outcomes and in-hospital mortality among hospitalized patients with COVID-19: a retrospective cohort study from Northern Iran

Article References: Zabihi, R., Abedi, S. H., Shirafkan, H., Dehpanah, A. A., Raei, A., Zebardast, A., & Yahyapour, Y. (2026). Association of chronic liver disease with clinical outcomes and in-hospital mortality among hospitalized patients with COVID-19: a retrospective cohort study from Northern Iran. Gut Pathogens. https://doi.org/10.1186/s13099-026-00888-4

Image Credits: AI Generated

DOI: 10.1186/s13099-026-00888-4

Keywords: COVID-19, chronic liver disease, cirrhosis, SARS-CoV-2, in-hospital mortality, clinical outcomes, retrospective cohort study, liver enzymes, hepatic encephalopathy, Iran, Gut Pathogens, coagulopathy

The research, published in the journal Gut Pathogens, tracked patients with Helicobacter pylori–associated precancerous stomach lesions over two years, repeatedly measuring levels of interleukin-8, a pro-inflammatory chemokine long implicated in the biology of gastric carcinogenesis. The findings indicate that the trajectory of IL-8 over time, rather than a single snapshot, carries meaningful predictive information about which patients will progress toward malignancy. In an era when precision oncology increasingly depends on molecular signals rather than gross symptoms, the study adds a potentially valuable piece to the biomarker puzzle.

The scientific rationale behind the work rests on the well-characterized inflammatory cascade that H. pylori initiates in the gastric mucosa. This bacterium colonizes the stomach lining of roughly half the global population, and while most carriers never fall ill, a subset develops a stepwise sequence of pathology: chronic gastritis, atrophic gastritis, intestinal metaplasia, and eventually adenocarcinoma. Interleukin-8 sits at a critical junction in this process. The chemokine is secreted by gastric epithelial cells and macrophages in response to H. pylori infection and acts as a potent recruiter of neutrophils, sustaining the chronic inflammatory milieu that drives DNA damage, cell turnover, and, ultimately, neoplastic transformation. Tumor cells themselves also produce IL-8, where it promotes angiogenesis, proliferation, and metastatic behavior, which makes the molecule interesting both as a consequence of inflammation and as a possible engine of cancer progression.

To test whether circulating IL-8 could serve as a practical surveillance tool, the investigators designed a multicenter, prospective longitudinal cohort study spanning five Egyptian centers. They enrolled 200 participants distributed across five groups: 50 patients with atrophic gastritis, 50 with intestinal metaplasia, 25 with H. pylori–positive gastric cancer, 25 with H. pylori–negative gastric cancer, and 50 healthy controls. Every participant underwent baseline clinical assessment, laboratory evaluation including the established tumor markers CEA and CA19-9, H. pylori testing by stool antigen assay and urea breath test performed according to the Maastricht VI consensus guidelines, and endoscopy with histopathology interpreted under the Updated Sydney System. Critically, the 100 patients with precancerous lesions were then followed for 24 months, with serum IL-8 measured at 0, 6, 12, 18, and 24 months and a repeat endoscopy performed at the end of the observation period.

The baseline cross-sectional results alone were striking. Mean serum IL-8 climbed in a stepwise fashion across the disease spectrum: healthy controls averaged 9.7 picograms per milliliter, patients with atrophic gastritis 42.1, those with intestinal metaplasia 64.8, and those with established gastric cancer 107.4, a gradient that was highly statistically significant. Notably, IL-8 elevation in cancer patients appeared independent of H. pylori status, with comparable levels in H. pylori–positive and H. pylori–negative tumors. The authors caution, however, that these stage-stratified subgroup comparisons involved small numbers and should be regarded as exploratory. Nevertheless, the pattern is biologically coherent: as the gastric mucosa marches through the precancerous cascade, the inflammatory chemokine burden in the circulation appears to rise in parallel, reflecting the escalating molecular chaos within the stomach wall.

The longitudinal data proved even more informative. Of the 100 patients with precancerous lesions, 94 completed the full follow-up, and 9 of them progressed to gastric cancer during the study, 7 from intestinal metaplasia and 2 from atrophic gastritis. Using a cutoff of 52.3 picograms per milliliter at baseline, elevated IL-8 was associated with subsequent progression, achieving an area under the receiver operating characteristic curve of 0.84, with sensitivity of 88.9 percent, specificity of 78.0 percent, and a negative predictive value of 98.5 percent. That last figure deserves emphasis: a normal IL-8 level at a given visit was an extraordinarily reassuring finding, correctly identifying nearly 99 percent of patients who did not go on to develop cancer within the follow-up window. The established markers fared far worse, with CEA yielding an AUC of 0.62 and CA19-9 an AUC of 0.58, both barely better than chance in this setting.

Because the true power of a surveillance biomarker lies in its performance over time, the researchers applied time-dependent ROC analysis using a cumulative and dynamic approach. The discriminatory capacity of serial IL-8 strengthened as follow-up accumulated: the time-dependent AUC rose to 0.91 at 12 months and reached 0.94 at 18 months. In other words, the longer the team watched a patient’s IL-8 curve, the more accurately they could distinguish the individuals on a path to malignancy from those whose lesions would remain stable. This dynamic behavior is precisely what one hopes for from a monitoring strategy, since clinical decisions about escalating endoscopic surveillance depend on recognizing change rather than on static risk estimates made once at enrollment.

To capture that change formally, the team employed group-based trajectory modeling, executed while blinded to outcome status, which stratified the 100 patients into three distinct patterns of IL-8 behavior: a Stable-Low group of 42 patients, a Moderate-Rising group of 49, and a High-Accelerating group of 9. Every single patient in the High-Accelerating group progressed to gastric cancer, and the acceleration point in their IL-8 curves preceded the clinical diagnosis by a median of six months, with a range of three to twelve months. The researchers are appropriately measured about this observation, describing it as exploratory and hypothesis-generating and stressing that external validation is required before any causal or firm clinical interpretation. Still, the notion that a molecular inflection point in the bloodstream can herald cancer’s arrival by half a year is a tantalizing clue for early detection.

The statistical analysis also grappled with a challenge familiar to anyone studying rare events: only 9 progression events occurred, which limits the power of conventional regression. The investigators therefore used multivariable logistic regression with Firth penalization, a technique designed to reduce bias in small-sample, low-event settings. In that model, baseline IL-8 emerged as an independent predictor of progression, with an adjusted odds ratio of 2.31 for every 10-picogram-per-milliliter increase (95 percent confidence interval 1.48 to 3.61), and the presence of intestinal metaplasia carried an adjusted odds ratio of 4.22 (95 percent confidence interval 1.31 to 13.61). The study’s conclusions additionally report an adjusted hazard ratio of 6.94 for a baseline IL-8 above 52.3 picograms per milliliter, reinforcing the same message: the chemokine’s concentration and the histological stage together define a high-risk profile that standard markers miss.

What would it take to translate these numbers into clinical practice? First, the authors and independent observers alike will want confirmation in larger, geographically diverse cohorts, since the event count here was small and Egypt’s specific epidemiology of gastric cancer may not generalize everywhere. Second, the operational logistics matter: the required IL-8 sampling schedule, assay standardization across laboratories, and cost-effectiveness relative to simply intensifying endoscopic surveillance all remain open questions. Third, a biomarker with 88.9 percent sensitivity and 78.0 percent specificity would likely function best as a triage tool, selecting which patients with atrophic gastritis or intestinal metaplasia need closer endoscopic follow-up rather than replacing endoscopy outright. Yet if the six- to twelve-month lead time observed in the High-Accelerating trajectory is reproduced, the payoff could be substantial, catching tumors at a stage when endoscopic resection can be curative. In a disease that claims hundreds of thousands of lives annually and disproportionately burdens regions where advanced endoscopic infrastructure is scarce, a cheap, repeatable blood test that watches the gastric precancerous cascade in real time would represent a genuinely meaningful advance, and this study offers the most rigorous longitudinal evidence to date that interleukin-8 might be exactly that signal.

Subject of Research: Serum interleukin-8 trajectories as biomarkers of progression from Helicobacter pylori–associated precancerous gastric lesions to gastric cancer

Article Title: Serial serum interleukin-8 trajectories are associated with progression from Helicobacter pylori–associated precancerous lesions to gastric cancer: a prospective longitudinal cohort study

Article References: Semeya, A. A., Abdel Hafez, R. S. A., Elgamal, R., Badr, A., Orabi, M. I., Younis, S. R., Morgan, M. M., Ahmed Hassan, M., Alawy, M. R., & Othman, A. A. A. (2026). Serial serum interleukin-8 trajectories are associated with progression from Helicobacter pylori–associated precancerous lesions to gastric cancer: a prospective longitudinal cohort study. Gut Pathogens. https://doi.org/10.1186/s13099-026-00876-8

Image Credits: AI Generated

DOI: 10.1186/s13099-026-00876-8

Keywords: gastric cancer, interleukin-8, Helicobacter pylori, atrophic gastritis, intestinal metaplasia, biomarker, early detection, prospective cohort study, inflammation, tumor markers, risk stratification, Gut Pathogens

The retracted paper, originally published on 19 May 2019 in Gut Pathogens under the title ‘Prevalence and pathologic effects of colibactin and cytotoxic necrotizing factor-1 (Cnf 1) in Escherichia coli: experimental and bioinformatics analyses,’ was authored by a team of Egyptian researchers working across two institutions. Radwa N. Morgan and Hala A. Farrag were affiliated with the Drug Radiation Research Department at the National Centre for Radiation Research and Technology, part of the Egyptian Atomic Energy Authority in Cairo, while Sarra E. Saleh and Mohammad M. Aboulwafa were based in the Microbiology and Immunology Department of the Faculty of Pharmacy at Ain Shams University, also in Cairo. Aboulwafa served as the corresponding author of the work.

The specific concerns documented in the retraction notice are detailed and methodical. Figure 1C and Figure 1F were found to partially overlap with each other, as were Figure 2C and Figure 2D. In addition, Figure 3D and Figure 3F showed partial overlap, and the two panels of Figure 6, panels a and b, also appeared to overlap. In each case, the overlapping images were supposed to depict different experimental conditions, meaning that identical or near-identical image regions had been used to represent results that should have been distinct. This pattern of duplication is one of the most common triggers for retractions in the scientific literature, because it undermines the reader’s ability to trust that the reported data were independently generated.

When such concerns are raised, the standard editorial process gives authors an opportunity to respond. In this instance, the retraction notice states plainly that the authors were unable to provide a satisfactory explanation or supporting data to address the concerns. Faced with unresolved questions about the integrity of the figures, the Editor-in-Chief concluded that the journal could no longer have confidence in the reliability of the research presented in the article, the formal threshold for a retraction under the guidelines that govern most scholarly publishers. Notably, the retraction is contested: Mohammad M. Aboulwafa has stated on behalf of all the authors that they disagree with the retraction. The retraction notice records this disagreement, which is standard practice, but a contested retraction still stands, and the article remains formally withdrawn from the scientific record.

The subject matter of the retracted study makes the retraction particularly relevant to researchers working on gut microbiology and bacterial pathogenesis. Colibactin is a genotoxin produced by certain strains of E. coli and related Enterobacteriaceae that live in the human gut. It is a polyketide-peptide hybrid molecule synthesized by enzymes encoded on the pks genomic island, and it works by cross-linking DNA in host cells. This DNA damage can trigger cell cycle arrest and cell death, and it has been implicated in the formation of characteristic mutational signatures found in colorectal cancer genomes. Because of this link to cancer biology, colibactin has been one of the most intensively studied bacterial toxins of the past decade, with laboratories around the world working to understand how it is produced, how it reaches host cells, and how its activity shapes the tumor microenvironment in the intestine.

Cytotoxic necrotizing factor 1, the second toxin examined in the retracted paper, is a different kind of weapon in the E. coli arsenal. Rather than damaging DNA, CNF1 is a bacterial protein toxin that permanently activates Rho GTPases, the molecular switches that control the actin cytoskeleton of host cells. By locking these switches in their active state, CNF1 causes dramatic cytoskeletal rearrangements, cell enlargement, and multinucleation, effects that contribute to tissue damage and inflammation. CNF1-producing strains are associated with urinary tract infections, meningitis, and other extraintestinal diseases, and the toxin has also been studied for its effects on epithelial barrier integrity and immune cell behavior. Studies of how prevalent these two virulence factors are in clinical and environmental E. coli populations, and what pathological effects they produce, sit squarely within the aims and scope of Gut Pathogens, which covers the microbiology, immunology, and pathogenesis of the gastrointestinal tract.

The retracted study combined laboratory experiments with bioinformatics analyses, an approach that has become increasingly common in microbiology as researchers pair phenotypic characterization of bacterial isolates with genomic and computational screening for virulence genes. Work of this kind typically involves collecting E. coli strains, testing them for the presence of toxin-encoding genes, measuring the pathological effects of toxin-producing isolates on cultured cells or model systems, and using computational tools to compare the genetic determinants of virulence across strains. Because such studies inform how scientists assess the disease potential of E. coli populations, retractions in this area matter to the wider field: findings that cannot be trusted may distort the perceived prevalence of dangerous toxin types or misdirect follow-up research.

The case also illustrates the ongoing evolution of post-publication peer review and image integrity screening. Journals and publishers increasingly use automated tools and expert forensic analysis to detect duplicated or manipulated images in published figures, and readers are encouraged to report concerns long after a paper’s publication date. The seven-year gap between the original publication in May 2019 and the retraction in September 2026 reflects the time such investigations can take, involving correspondence between the journal, the authors, and their institutions, and the careful documentation of specific figure-level concerns. The retraction notice itself is open access, ensuring that anyone who encounters the original paper through databases or citation trails will be directed to the notice explaining why the article was withdrawn.

For the research community, the practical consequences of a retraction are significant. The retracted article should no longer be cited as reliable evidence, and databases such as PubMed and the journal’s own website will flag it as retracted. The original article remains accessible online, as is standard practice, but it is watermarked and linked to the retraction notice so that readers understand its status. The authors’ disagreement with the retraction does not alter this status; the editorial decision rests on the journal’s judgment that the reliability of the findings cannot be assured. The retraction notice also notes that the article was published open access under a Creative Commons license, and Springer Nature’s standard publisher’s note regarding jurisdictional claims applies to the notice itself.

The broader lesson for microbiology and for science publishing is that the credibility of research on bacterial virulence factors depends on the integrity of the underlying experimental data. Colibactin and CNF1 remain genuine and important subjects of investigation, with well-documented roles in DNA damage, colorectal carcinogenesis, and cytoskeletal toxicity, and legitimate research on these toxins continues across many laboratories. Questions about the prevalence of toxin-producing E. coli strains and their pathological effects remain scientifically important, and they will be answered, as always, by studies whose figures, data, and analyses can withstand scrutiny. The retraction of this particular paper removes one unreliable data point from the literature while leaving the underlying scientific questions open for future, verifiable work.

Subject of Research: Retraction of a study on colibactin and cytotoxic necrotizing factor 1 production by Escherichia coli

Article Title: Retraction Note: Prevalence and pathologic effects of colibactin and cytotoxic necrotizing factor‑1 (Cnf 1) in Escherichia coli: experimental and bioinformatics analyses

Article References: Morgan, R. N., Saleh, S. E., Farrag, H. A., & Aboulwafa, M. M. (2026). Retraction Note: Prevalence and pathologic effects of colibactin and cytotoxic necrotizing factor‑1 (Cnf 1) in Escherichia coli: experimental and bioinformatics analyses. Gut Pathogens, 18(1), Article 75. https://doi.org/10.1186/s13099-026-00882-w

Image Credits: AI Generated

DOI: 10.1186/s13099-026-00882-w

Keywords: Escherichia coli, colibactin, CNF1, bacterial toxins, retraction, Gut Pathogens, research integrity, image duplication, gut microbiology, virulence factors, post-publication review, Springer Nature

The research, led by Guangpin Zeng of the People’s Hospital of Wenshan Prefecture together with Linran Zeng of Yuxi Zhongshan Hospital and Yinrong Zhu of the People’s Hospital of Wenshan, analyzed health-screening data from 6,998 adults collected in Wenshan between 2020 and 2024. The region was chosen deliberately: high-prevalence areas such as Southwest China offer the statistical power needed to detect even modest associations between infection status and metabolic markers. The cohort, drawn from a routine health-screening program, represents one of the larger single-population datasets assembled to examine this question, giving the findings unusual weight in a literature often dominated by small, heterogeneous studies.

At the center of the investigation was the triglyceride-glucose index, universally abbreviated as the TyG index. This simple mathematical measure—calculated as the natural logarithm of fasting triglycerides in milligrams per deciliter multiplied by fasting glucose in milligrams per deciliter, divided by two—has emerged in the past decade as a cheap, validated surrogate for insulin resistance. Unlike the hyperinsulinemic-euglycemic clamp, the labor-intensive gold standard that few clinical settings can justify for screening purposes, the TyG index requires nothing more than two values already present in virtually every routine blood panel. That accessibility has made it a favorite tool for large-scale epidemiological studies probing the metabolic consequences of infections, lifestyle factors, and chronic diseases.

Diagnosing H. pylori infection in the cohort relied on the carbon-14 urea breath test, a well-established technique that exploits the bacterium’s defining biochemical trick: its ability to produce urease, an enzyme that breaks down urea into carbon dioxide and ammonia. Participants ingested a small dose of carbon-14-labeled urea, and any H. pylori colonies in the stomach converted it into labeled carbon dioxide detectable in exhaled breath. A result exceeding 50 disintegrations per minute was classified as positive. The test is noninvasive, reasonably accurate, and widely deployed in Chinese screening programs, making it a practical choice for a study of this scale.

The raw numbers told what initially looked like an intriguing story. Of the 6,998 participants, 2,736—39.1 percent—tested positive for H. pylori, a prevalence consistent with the region’s reputation as a high-burden area. Those who carried the bacterium had a slightly but statistically significantly higher TyG index than their uninfected counterparts: 8.83 plus or minus 0.73 versus 8.76 plus or minus 0.70, a difference with a p-value below 0.001. In the univariate analysis, each unit increase in the TyG index was associated with roughly a 14 percent higher odds of infection, with an odds ratio of 1.14 and a 95 percent confidence interval of 1.06 to 1.21. On its face, the data appeared to support the idea that insulin resistance and H. pylori colonization travel together.

That impression evaporated under multivariable scrutiny. Once the researchers adjusted for age and sex—arguably the two most fundamental demographic confounders in any epidemiological analysis—the association collapsed. The adjusted odds ratio fell to 1.022, with a confidence interval spanning 0.950 to 1.100 and a p-value of 0.553, indistinguishable from no effect. Further statistical refinement, adding total bilirubin, alkaline phosphatase, gamma-glutamyl transferase, and low-density lipoprotein cholesterol to the model, did nothing to resurrect the signal. In the fully adjusted model, the only independent correlates of infection were age, male sex, and total bilirubin—demographic and biochemical characteristics, not metabolic state as captured by the TyG index.

The researchers went beyond conventional regression to stress-test their conclusions. Restricted cubic splines were used to model the relationship between the TyG index and infection flexibly, allowing the team to detect any nonlinear patterns that a simple linear term might miss. Stratified analyses examined whether the association might emerge only in particular subgroups—older participants, men, or people with specific liver enzyme profiles. Neither approach uncovered a hidden association. The pattern was consistent: whatever crude relationship existed in the unadjusted data was an artifact of demographic composition, not a genuine physiological link between the bacterium and insulin resistance.

Why would age and sex so thoroughly masquerade as a metabolic signal? The answer lies in the tangled web of correlations that characterizes observational health data. Older adults tend to have both higher rates of cumulative H. pylori exposure—having grown up in eras with poorer sanitation and higher transmission—and less favorable metabolic profiles. Men in this population, as in many others, showed different infection rates and different lipid and glucose levels than women. When such variables are left out of a statistical model, their effects bleed into whatever exposure-outcome relationship the model is testing, producing odds ratios that look meaningful but reflect demographic structure rather than biology. The Wenshan team’s findings suggest that earlier positive reports linking H. pylori to insulin resistance may have suffered from precisely this problem.

The authors are explicit about the practical implication: the TyG index should not be considered an independent marker or a screening tool for H. pylori infection, and clinicians have no basis for using metabolic panels to infer who might be carrying the bacterium. But the study’s larger contribution may be methodological. By demonstrating how dramatically a seemingly robust univariate association can dissolve under rigorous adjustment, the paper serves as a cautionary template for future research on infection-metabolism links. The team calls for prospective, longitudinal studies employing direct measures of insulin resistance—such as clamp techniques or validated surrogate indices tracked over time—to settle the question definitively, rather than relying on cross-sectional snapshots vulnerable to confounding.

The findings land at a moment of intense interest in the extragastric effects of H. pylori, with proposed connections ranging from cardiovascular disease to non-alcoholic fatty liver disease and neurodegeneration. Each of these hypotheses faces the same analytical gauntlet that the TyG question just failed to clear in this population: distinguishing true biological causation from the demographic and lifestyle factors that cluster around both infection and metabolic disease. For now, the message from Wenshan is one of disciplined skepticism. A bacterium that colonizes half of humanity certainly does something to the body—but according to this large, carefully adjusted analysis, distorting insulin sensitivity as measured by the TyG index does not appear to be among those things, at least not in the high-risk communities of Southwest China.

Subject of Research: The association between Helicobacter pylori infection and the triglyceride-glucose index as a marker of insulin resistance in a high-risk Chinese population

Article Title: Beyond the stomach: a cross-sectional analysis of H. pylori infection and the TyG index in a high-risk population from Southwest China

Article References: Zeng, G., Zeng, L., & Zhu, Y. (2026). Beyond the stomach: a cross-sectional analysis of H. pylori infection and the TyG index in a high-risk population from Southwest China. Gut Pathogens. https://doi.org/10.1186/s13099-026-00884-8

Image Credits: AI Generated

DOI: 10.1186/s13099-026-00884-8

Keywords: Helicobacter pylori, TyG index, insulin resistance, cross-sectional study, Southwest China, Gut Pathogens, metabolic syndrome, inflammation, urea breath test, confounding, epidemiology, gastroenterology